Article Text

PDF
Effects of Diet and Gemfibrozil on Posttransplant Hyperlipidemia in Renal Transplant Recipients
  1. Muzaffer Sapan, MD*,
  2. Beste Ozben, MD,
  3. Gulsen Yakupoglu, MD*,
  4. Gultekin Suleymanlar, MD*,
  5. Tomris Ozben, PhD
  1. From the Department of *Nephrology, Akdeniz University, Medical Faculty, Antalya; †Department of Cardiology, Marmara University, Medical Faculty, Istanbul; and ‡Department of Biochemistry, Akdeniz University, Medical Faculty, Antalya, Turkey.
  1. Received July 16, 2008, and in revised form December 5, 2008.
  2. Accepted for publication December 5, 2008.
  3. Reprints: Tomris Ozben, PhD, Akdeniz University, Medical Faculty, Department of Biochemistry, 07070 Antalya, Turkey (e-mail: ozben{at}akdeniz.edu.tr).
  4. This study was supported by Akdeniz University Research Fund.

Abstract

Background Posttransplant hyperlipidemia increases cardiovascular morbidity and mortality rate in renal transplant recipients. It also leads to graft loss due to atherosclerosis and glomerular damage. It is essential to control hyperlipidemia in renal transplant recipients to prevent these events.

Methods In our study, we determined lipid profiles in 59 renal transplant recipients. Twenty of the recipients had hyperlipidemia; 9 had type IV, and 11 had type II hyperlipoproteinemia. Randomly selected 14 of 20 hyperlipidemic patients consisted of the diet group and were treated with American phase 3 diet for 1 month. Randomly selected 6 of the 20 hyperlipidemic patients received their regular diet as the control group. Five diet-resistant patients in the American phase 3 diet group were given diet plus placebo for another 1 month and then they were given diet plus Gemfibrozil (600 mg twice a day) for 2 months.

Results Lipid profile was normalized in 9 of the 14 patients on American phase 3 diet. The lipid profile of 5 patients in the American phase 3 diet group did not change significantly after 1-month diet. These 5 diet-resistant patients were given diet plus placebo for another 1 month, and their lipid levels again did not change significantly. Afterward, they were treated with Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months. At the end of this therapy period, their cholesterol level and triglyceride level decreased significantly. No change was observed in low-density lipoprotein cholesterol and high-density lipoprotein cholesterol levels.

Conclusions We conclude that American phase 3 diet and/or Gemfibrozil are effective in controlling posttransplant hyperlipidemia in renal transplant recipients.

Key Words
  • Gemfibrozil
  • hyperlipidemia
  • renal transplantation
  • American phase 3 diet

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.